{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:05:58Z","timestamp":1775736358150,"version":"3.50.1"},"reference-count":108,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.heliyon.2024.e29997","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T18:07:54Z","timestamp":1713722874000},"page":"e29997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma"],"prefix":"10.1016","volume":"10","author":[{"given":"Jin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e29997_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2024.e29997_bib2","first-page":"211","article-title":"Studies on conditions associated with disturbed gamma globulin formation (gammopathies)","volume":"56","author":"Waldenstrom","year":"1960","journal-title":"Harvey Lect."},{"key":"10.1016\/j.heliyon.2024.e29997_bib3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0025-6196(25)38163-2","article-title":"3. The laboratory investigation of monoclonal gammopathies","volume":"53","author":"Kyle","year":"1978","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.heliyon.2024.e29997_bib4","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am. J. Med."},{"key":"10.1016\/j.heliyon.2024.e29997_bib5","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e29997_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/asheducation-2010.1.295","article-title":"Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology","volume":"2010","author":"Landgren","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.heliyon.2024.e29997_bib7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2010.11.003","article-title":"Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma","volume":"48","author":"Zingone","year":"2011","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib8","article-title":"Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance","volume":"12","author":"Mejia","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib9","first-page":"9932","article-title":"The role of Wnt\/beta-catenin signaling pathway in the pathogenesis and treatment of multiple myeloma","volume":"13","author":"Yuan","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.heliyon.2024.e29997_bib10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1159\/000520312","article-title":"Multiple myeloma: molecular pathogenesis and disease evolution","volume":"44","author":"Heider","year":"2021","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.heliyon.2024.e29997_bib11","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1038\/s41467-022-33944-z","article-title":"Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis","volume":"13","author":"Boiarsky","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e29997_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.842200","article-title":"Single-cell proteomics and tumor RNAseq identify novel pathways associated with clofazimine sensitivity in PI- and IMiD- resistant myeloma, and putative stem-like cells","volume":"12","author":"Kumar","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","article-title":"Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine","volume":"19","author":"Dutta","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib14","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41598-020-80607-4","article-title":"Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e29997_bib15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/10428190500085024","article-title":"The adverse prognostic impact of advanced age in multiple myeloma","volume":"46","author":"Mileshkin","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.heliyon.2024.e29997_bib16","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.clml.2022.04.013","article-title":"Lack of renal recovery predicts poor survival in patients of multiple myeloma with renal impairment","volume":"22","author":"Sharma","year":"2022","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.heliyon.2024.e29997_bib17","article-title":"Prognostic potential of heart rate and hypertension in multiple myeloma patients","volume":"8","author":"Wang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.heliyon.2024.e29997_bib18","article-title":"Near tetrapoloid karyotype with translocation t(11;14) in a Moroccan patient with amyloid light-chain amyloidosis and multiple myeloma","volume":"14","author":"Hamdaoui","year":"2020","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.heliyon.2024.e29997_bib19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12288-019-01215-5","article-title":"Conventional cytogenetics and interphase fluorescence in situ hybridization results in multiple myeloma: a Turkey laboratory analysis of 381 cases","volume":"36","author":"Aydin","year":"2020","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.heliyon.2024.e29997_bib20","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/j.clml.2021.10.008","article-title":"Impact of etiological cytogenetic abnormalities on the depth of immunoparesis and survival in newly diagnosed multiple myeloma","volume":"22","author":"Caro","year":"2022","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.heliyon.2024.e29997_bib21","first-page":"41","article-title":"Cytogenetics of multiple myeloma","volume":"34","author":"Trcic","year":"2010","journal-title":"Coll. Antropol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib22","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bbmt.2013.05.017","article-title":"Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma","volume":"19","author":"Sasaki","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.heliyon.2024.e29997_bib23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/gcc.22372","article-title":"Translocation t(11;14) in newly diagnosed patients with multiple myeloma: is it always favorable?","volume":"55","author":"Leiba","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.heliyon.2024.e29997_bib24","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/ejh.13325","article-title":"Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?","volume":"103","author":"Gran","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib25","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2024.e29997_bib26","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.clml.2013.07.003","article-title":"Multiple myeloma international staging system: \"staging\" or simply \"aging\" system?","volume":"13","author":"Bataille","year":"2013","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.heliyon.2024.e29997_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101153","article-title":"Genomic profiling of multiple myeloma: new insights and modern technologies","volume":"33","author":"Hultcrantz","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/394792","article-title":"Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future","volume":"2014","author":"Ozaki","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.heliyon.2024.e29997_bib30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s12325-022-02355-3","article-title":"The MODIFY study protocol: an open-label, single-arm, multicenter, prospective pragmatic study of ixazomib-based triple-drug therapy in Chinese patients with multiple myeloma","volume":"40","author":"Chen","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.heliyon.2024.e29997_bib31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.18025","article-title":"Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019","volume":"197","author":"Swan","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib32","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S2352-3026(22)00350-7","volume":"10","author":"Yong","year":"2023","journal-title":"Lancet Haematol"},{"issue":"Suppl","key":"10.1016\/j.heliyon.2024.e29997_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1188\/13.CJON.S2.33-41","article-title":"Clinical updates in blood and marrow transplantation in multiple myeloma","volume":"17","author":"Faiman","year":"2013","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.heliyon.2024.e29997_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.983220","article-title":"Hematopoietic stem cell transplantation from HLA-matched sibling donors in children with acute lymphoblastic leukemia: a report from the Children's Cancer Hospital Egypt","volume":"12","author":"Hammad","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib35","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/cncr.32060","article-title":"Is there still a role for stem cell transplantation in multiple myeloma?","volume":"125","author":"Mina","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2024.e29997_bib36","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3324\/haematol.2021.280394","article-title":"All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study","volume":"107","author":"Touzeau","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2024.e29997_bib37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12185-022-03338-4","article-title":"Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment","volume":"116","author":"Matsue","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100616","article-title":"Treatment of relapsed multiple myeloma: evidence-based recommendations","volume":"39","author":"Durer","year":"2020","journal-title":"Blood Rev."},{"key":"10.1016\/j.heliyon.2024.e29997_bib39","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clml.2021.10.013","article-title":"Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma","volume":"22","author":"Costa","year":"2022","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.heliyon.2024.e29997_bib41","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/ajhp\/zxac091","article-title":"New and emerging pharmacotherapies for the management of multiple myeloma","volume":"79","author":"Moore","year":"2022","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.heliyon.2024.e29997_bib42","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e29997_bib43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13148-022-01306-7","article-title":"Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression","volume":"14","author":"Cao","year":"2022","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.heliyon.2024.e29997_bib44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.56875\/2589-0646.1035","article-title":"Next-generation chimeric antigen receptor T-cells","volume":"15","author":"Yi","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.heliyon.2024.e29997_bib45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e29997_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235996","article-title":"Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, imid and anti-CD-38 from a German registry","volume":"13","author":"Merz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e29997_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clml.2022.09.001","article-title":"Recent advances in the use of chimeric antigen receptor-expressing T-cell therapies for treatment of multiple myeloma","volume":"23","author":"Martin","year":"2023","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.heliyon.2024.e29997_bib48","article-title":"Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1)","author":"Mi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib49","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/03007995.2022.2139052","article-title":"Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"39","author":"Martin","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.heliyon.2024.e29997_bib51","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e29997_bib52","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11899-017-0373-2","article-title":"CARs in the lead against multiple myeloma","volume":"12","author":"Ormhoj","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.heliyon.2024.e29997_bib54","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.heliyon.2024.e29997_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e29997_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/sci-2020-029","article-title":"Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma","volume":"8","author":"Ding","year":"2021","journal-title":"Stem Cell Invest."},{"key":"10.1016\/j.heliyon.2024.e29997_bib57","article-title":"Chimeric antigen receptor T cell therapy and its significance in multiple myeloma","volume":"13","author":"Padda","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.heliyon.2024.e29997_bib58","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41416-018-0346-9","article-title":"Cell-based immunotherapy approaches for multiple myeloma","volume":"120","author":"Kriegsmann","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e29997_bib59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.15698\/cst2022.11.273","article-title":"Unraveling the surface proteomic profile of multiple myeloma to reveal new immunotherapeutic targets and markers of drug resistance","volume":"6","author":"Patino-Escobar","year":"2022","journal-title":"Cell Stress"},{"key":"10.1016\/j.heliyon.2024.e29997_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115894","article-title":"A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy","volume":"437","author":"Wang","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib95","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e29997_bib96","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: a target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib97","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e29997_bib98","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-019-1092-1","article-title":"Recent updates on CAR T clinical trials for multiple myeloma","volume":"18","author":"Lin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.heliyon.2024.e29997_bib99","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3324\/haematol.2020.276402","article-title":"European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma","volume":"106","author":"Bruno","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2024.e29997_bib100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.23736\/S0031-0808.20.04146-4","article-title":"CAR T cells targeting options in the fight against multiple myeloma","volume":"63","author":"Nicolini","year":"2021","journal-title":"Panminerva Med."},{"key":"10.1016\/j.heliyon.2024.e29997_bib101","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e29997_bib102","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.heliyon.2024.e29997_bib61","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.heliyon.2024.e29997_bib62","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.heliyon.2024.e29997_bib63","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fernandez de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.heliyon.2024.e29997_bib64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib65","first-page":"904","article-title":"Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.heliyon.2024.e29997_bib66","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","article-title":"Dual targeting with CAR T cells to limit antigen escape in multiple myeloma","volume":"1","author":"Simon","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.heliyon.2024.e29997_bib67","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib103","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib104","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1959102","article-title":"Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma","volume":"10","author":"Feng","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.heliyon.2024.e29997_bib68","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e29997_bib105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40364-020-00192-6","article-title":"Characterization of novel dual tandem CD19\/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma","volume":"8","author":"Kang","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.heliyon.2024.e29997_bib106","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-20-0118","article-title":"Treatment of multiple myeloma using chimeric antigen receptor T cells with dual specificity","volume":"8","author":"Globerson Levin","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.heliyon.2024.e29997_bib107","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5562630","article-title":"Selective cytotoxicity of single and dual anti-CD19 and anti-cd138 chimeric antigen receptor-natural killer cells against hematologic malignancies","volume":"2021","author":"Luanpitpong","year":"2021","journal-title":"J Immunol Res"},{"key":"10.1016\/j.heliyon.2024.e29997_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092523","article-title":"Bispecific chimeric antigen receptor T cell therapy for B cell malignancies and multiple myeloma","volume":"12","author":"Cronk","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e29997_bib69","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib70","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib71","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/neuonc\/noy045","article-title":"Comment on \"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma\"","volume":"20","author":"Caruso","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib72","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/neuonc\/noy079","article-title":"Response to the comment on \"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma\" by Bielamowicz et al","volume":"20","author":"Joseph","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib73","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-17-1298","article-title":"Enhancing the potency and specificity of engineered T cells for cancer treatment","volume":"8","author":"Sukumaran","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.heliyon.2024.e29997_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc6401","article-title":"Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models","volume":"13","author":"Schneider","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e29997_bib75","article-title":"Novel technologies for improving the safety and efficacy of CAR-T cell therapy","author":"Ohta","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib76","doi-asserted-by":"crossref","first-page":"100","DOI":"10.56875\/2589-0646.1029","article-title":"Management of CAR T-cell related toxicities: what did the learning curve teach us so far?","volume":"15","author":"Murthy","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.heliyon.2024.e29997_bib77","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","article-title":"Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered T cells","volume":"25","author":"Drent","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e29997_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.heliyon.2024.e29997_bib79","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib80","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.beha.2017.09.002","article-title":"Cytokine release syndrome: who is at risk and how to treat","volume":"30","author":"Frey","year":"2017","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib81","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4049\/jimmunol.2001249","article-title":"Biomarkers for predicting cytokine release syndrome following CD19-targeted CAR T cell therapy","volume":"206","author":"Tedesco","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5209","article-title":"Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel","volume":"10","author":"Martin-Rojas","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.heliyon.2024.e29997_bib83","first-page":"160","article-title":"Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma","volume":"51","author":"Zu","year":"2022","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.heliyon.2024.e29997_bib84","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.heliyon.2024.e29997_bib85","article-title":"Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment","volume":"14","author":"Gu","year":"2022","journal-title":"WIREs Mech Dis"},{"key":"10.1016\/j.heliyon.2024.e29997_bib86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11940-019-0580-3","article-title":"Chimeric antigen receptor T cell-related neurotoxicity: mechanisms, clinical presentation, and approach to treatment","volume":"21","author":"Rice","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.heliyon.2024.e29997_bib87","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.heliyon.2024.e29997_bib88","first-page":"2365","article-title":"[Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies]","volume":"57","author":"Oh","year":"2016","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.heliyon.2024.e29997_bib89","article-title":"[Management of neurotoxicity following CAR-T cell therapy: recommendations of the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)]","author":"Picard","year":"2022","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.heliyon.2024.e29997_bib90","doi-asserted-by":"crossref","DOI":"10.1177\/15347354221114142","article-title":"Prevention of bortezomib-induced peripheral neuropathy in newly multiple myeloma patients using nervonic acid, curcuma rizoma, and L-arginine compound: a pilot study","volume":"21","author":"Maschio","year":"2022","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.heliyon.2024.e29997_bib91","article-title":"Acute kidney injury after CAR-T cell infusion","author":"Rousseau","year":"2022","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.heliyon.2024.e29997_bib92","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ckj\/sfab292","article-title":"Treatment of acute kidney injury in cancer patients","volume":"15","author":"Braet","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.heliyon.2024.e29997_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/cells11243991","article-title":"Acute kidney injury in cancer immunotherapy recipients","volume":"11","author":"Joseph","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e29997_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133230","article-title":"Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024060286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024060286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:20:45Z","timestamp":1775733645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024060286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":108,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2405844024060286"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e29997","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e29997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e29997"}}